PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Athira Pharma announces publication in Frontiers in Neuroscience highlighting therapeutic potential of ATH-1105 in amyotrophic lateral sclerosis (ALS)

Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS

2024-02-08
(Press-News.org) BOTHELL, WA, Feb. 8, 2024 — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced publication of research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of amyotrophic lateral sclerosis (ALS). The original research article, “ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS,” authored by Berthiaume, A., and Reda, S., et al., was published in the peer-reviewed journal, Frontiers in Neuroscience. ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.

 

“These data demonstrate that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS. Through enhancement of the neurotrophic HGF system, ATH-1105 protects spinal motor neurons from ALS-relevant insults in vitro and in animal models of ALS, prevents the progressive decline of motor and nerve function, reduces inflammation, preserves body weight and extends survival. Also, the significant reduction in plasma neurofilament light chain (NfL) levels, an established biomarker of neurodegeneration in ALS, is highly encouraging,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira. “These studies further support the therapeutic potential and continued development of ATH-1105, which is targeted to advance into first-in-human studies this year.”

 

Key findings highlighted in the publication include:

ATH-1105 enhances neurotrophic HGF system signaling and protects primary neuron cultures from various insults relevant to ALS. ATH-1105 treatment reduced astrocyte reactivity in spinal motor neuron-astrocyte co-cultures and preserved neuromuscular junction integrity in spinal motor neuron-muscle co-cultures following exposure to toxic levels of glutamate, believed to be a key driver of ALS pathology. In a TDP-43 mouse model of ALS, ATH-1105 treatment significantly preserved body weight, reduced motor and nerve function decline over time, decreased plasma biomarkers of inflammation and neurodegeneration, prevented axonal degeneration and TDP-43 pathology in peripheral nerves, and ultimately extended survival.  

“There is an urgent need for new ALS treatment options, particularly those aimed at slowing or stopping neurodegeneration,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira. “The results reported in this peer-reviewed publication suggest that ATH-1105 demonstrated consistent translation of neuroprotective and anti-inflammatory effects from in vitro to in vivo models, which led to improved motor function and survival in an ALS animal model. These findings further support our plans to progress ATH-1105 into first-in-human studies in the first half of 2024.”

 

The article is available on the Frontiers in Neuroscience website and from the Scientific Publications & Presentations page of the company’s website at www.athira.com.

 

About ATH-1105
ATH-1105 is an orally administered small molecule designed to positively modulate the neurotrophic hepatocyte growth factor (HGF) system, which plays a critical role in nervous system maintenance and repair, including stimulation of cell survival, increase in neuronal outgrowth and modulation of neuronal network repair. In preclinical models of amyotrophic lateral sclerosis (ALS), ATH-1105 has been shown to significantly increase survival, enhance motor and nerve function, reduce peripheral nerve demyelination and axon degeneration, and improve neurodegeneration and inflammation.

 

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton (ATH-1017), which is being evaluated for the potential treatment of mild-to-moderate Alzheimer’s disease in the Phase 2/3 LIFT-AD trial that is targeted to report topline data in the second half of 2024. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn, X (formerly known as Twitter) and Instagram. 

 

Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: product candidates as a potential treatment for amyotrophic lateral sclerosis, Alzheimer’s disease and other neurodegenerative diseases; future development plans; the anticipated reporting of data; expectations regarding the potential efficacy and commercial potential of Athira’s product candidates; and Athira’s ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “on track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,” “continue,” “suggest,” “potential,” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of Athira’s product candidates; development of product candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against Athira, its directors and officers; possible negative interactions of Athira's product candidates with other treatments; Athira’s assumptions regarding its financial condition and the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira’s clinical development plans as a result of pandemics or health epidemics, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira’s filings with the Securities and Exchange Commission from time to time. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

END


ELSE PRESS RELEASES FROM THIS DATE:

Sex hormones help gonorrhea fight off antimicrobials and antibiotics

2024-02-08
DURHAM, N.C. – You know that package warning that oral birth control won’t prevent STIs? Well in the case of gonorrhea, the sexually transmitted bacterium that causes the disease can use those hormones to help it resist antibiotic attacks. Like many bacteria, this bug, Neisseria gonorrhoeae, is equipped with pumps to push the killing chemicals out of its cells. But what’s unique, according to a Duke and Emory study online this week in Nature Communications, is that the hormones of the human urogenital tract actually allow gonorrhea to make and use more of these pumps to fight intrinsic ...

45 finalists named for the 2024 Hertz Fellowships

2024-02-08
The Fannie and John Hertz Foundation today announced 45 finalists for the 2024 Hertz Fellowships in applied science, mathematics and engineering. Selected from more than 860 applicants and representing 21 universities, the finalists advance to a culminating round of interviews for one of the most competitive and coveted doctoral fellowships in the nation. The 2024 class of Hertz Fellows will be announced in May. Since 1963, the Hertz Foundation has granted fellowships empowering the nation’s most promising young ...

How one type of lung cancer can transform into another

How one type of lung cancer can transform into another
2024-02-08
Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment. Researchers at Weill Cornell Medicine have developed a mouse model that illuminates this problematic process, known as histological transformation. The findings advance the understanding of how mutated genes can trigger cancer evolution and suggest targets for more effective treatments. The researchers, whose results were published ...

Results from South Pole Telescope’s new camera emerge

Results from South Pole Telescope’s new camera emerge
2024-02-08
Argonne is part of a multi-institutional effort to survey the sky for clues about the origins and nature of our universe. For more than five years, scientists at the South Pole Telescope in Antarctica have been observing the sky with an upgraded camera. The extended gaze toward the cosmos is picking up remnant light from the universe’s early formation. Now researchers have analyzed an initial batch of data, publishing details in the journal Physical Review D. The results from this limited dataset hint at even more powerful future insights about the nature of our universe. The telescope at the Amundsen-Scott South Pole Station, which is operated by the National ...

Rosenthal Department of Management established at McCombs School of Business

Rosenthal Department of Management established at McCombs School of Business
2024-02-08
AUSTIN, Texas — The Management Department in the McCombs School of Business at The University of Texas at Austin has long been recognized as a powerhouse for research excellence and teaching innovation. Now, it holds a new distinction. It is the first academic department in the business school to be named as the result of a generous gift. The newly named Rozanne and Billy Rosenthal Department of Management has been made possible by a $25 million gift from two married Longhorns, Rozanne Rosenthal, B.S. ’74, and Billy Rosenthal, BBA ’72. ...

Professor of Finance named ECGI Fellow

Professor of Finance named ECGI Fellow
2024-02-08
AUSTIN, Texas -- In recognition of her research and scholarship, Laura Starks, a professor of finance at The University of Texas at Austin, was recently named a fellow of the European Corporate Governance Institute (ECGI). She is among eight new fellows selected from academia in Europe and the United States. ECGI, founded in 2002, is an international scientific nonprofit association that serves as a forum on corporate governance among academics, legislators, and practitioners. Starks is the George Kozmetsky Centennial University Distinguished Chair in the McCombs School of ...

NJIT researchers unveil method to detect 'forever chemicals' in under 3 minutes

2024-02-08
PFAS have earned the name “forever chemicals” with good reason — the man-made compounds, which can take thousands of years to degrade and are found in everything from grease-resistant food packaging to water-repellent clothing, have made their way into nearly half the U.S. tap water supply. Now, in a study featured in Elsevier’s Journal of Hazardous Materials, New Jersey Institute of Technology chemists have demonstrated a new lab-based method to detect traces of PFAS from food packaging material, water and soil samples in just three minutes or less. Researchers say their approach could ...

Exploring new futures in space: a revolutionary integration of neuroscience, quantum physics, and space exploration

Exploring new futures in space: a revolutionary integration of neuroscience, quantum physics, and space exploration
2024-02-08
February 8, 2024, Mountain View, CA — The SETI Institute, leading humanity's quest to understand the origins and prevalence of life and intelligence in the universe and share that knowledge with the world, is pioneering innovative approaches to understanding our place in the cosmos. The SETI Institute is proud to support a groundbreaking project from London-based filmmaker and SETI Institute Designer of Experiences Dr. Nelly Ben Hayoun-Stépanian that combines insights from intergenerational trauma, neuroscience, quantum physics, and ...

Technique could improve the sensitivity of quantum sensing devices

2024-02-08
In quantum sensing, atomic-scale quantum systems are used to measure electromagnetic fields, as well as properties like rotation, acceleration, and distance, far more precisely than classical sensors can. The technology could enable devices that image the brain with unprecedented detail, for example, or air traffic control systems with precise positioning accuracy. As many real-world quantum sensing devices are emerging, one promising direction is the use of microscopic defects inside diamonds to create “qubits” that can be used for quantum sensing. Qubits are the building blocks of quantum ...

New process allows full recovery of starting materials from tough polymer composites

New process allows full recovery of starting materials from tough polymer composites
2024-02-08
In a win for chemistry, inventors at the Department of Energy’s Oak Ridge National Laboratory have designed a closed-loop path for synthesizing an exceptionally tough carbon-fiber-reinforced polymer, or CFRP, and later recovering all of its starting materials. A lightweight, strong and tough composite material, CFRP is useful for reducing weight and increasing fuel efficiency of automobiles, airplanes and spacecraft. However, conventional CFRPs are difficult to recycle. Most have been single-use materials, so their carbon footprint is significant. By contrast, ORNL’s closed-loop ...

LAST 30 PRESS RELEASES:

UC Irvine receives $15 million NSF grant for integrative movement research

University of Houston engineer Metin Akay featured in study highlighting 50 scientists' contributions to biomedical engineering advancements

JWST captures the end of planet formation

Good news—MS drugs taken while breastfeeding may not affect child development

Programs intended to reduce health insurance premiums may make coverage less affordable for the middle class

PrEP discontinuation in a US national cohort of sexual and gender minority populations, 2017–22

USC Study: Medicare Part D plans increased restrictions on drug coverage

Sacituzumab govitecan plus platinum-based chemotherapy in breast, bladder, and lung carcinomas

Global study unveils "problematic" use of porn

Newly discovered protein prevents DNA triplication

Less ice in the arctic ocean has complex effects on marine ecosystems and ocean productivity

Antarctica’s coasts are becoming less icy

New research shows migrating animals learn by experience

Modeling the origins of life: New evidence for an “RNA World”

Scientists put forth a smarter way to protect a smarter grid

An evolutionary mystery 125 million years in the making

Data science approach to identifying thermal conductivity-related structural factors in amorphous materials

Deciphering the male breast cancer genome

Detection of suicide-related emergencies among children using real-world clinical data: A free webinar from the Brain & Behavior Research Foundation

Editor-in-Chief of Sustainability and Climate Change Madhavi Venkatesan named USA TODAY Woman of the Year for Massachusetts for leading plastic bottle ban efforts

Tests show high-temperature superconducting magnets are ready for fusion

Zika vaccine safe, effective when administered during pregnancy

Firearm ownership is correlated with elevated lead levels in children, study finds

Role of African women and young people in agricultural service provision investigated in new CABI-led study

26th International Conference of the Redox Medicine Society Set for June 2024 in Paris, France

Geologists explore the hidden history of Colorado’s Spanish Peaks

Webb unlocks secrets of one of the most distant galaxies ever seen

3D-printed skin closes wounds and contains hair follicle precursors

Discovered a RNA molecule that helps prevent DNA replication errors

Small and overlooked: Amount of repetitive DNA in blood hints at cancer early

[Press-News.org] Athira Pharma announces publication in Frontiers in Neuroscience highlighting therapeutic potential of ATH-1105 in amyotrophic lateral sclerosis (ALS)
Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS